Radioactive 'Seek-and-Treat' drug tested in advanced cancer patients
NCT ID NCT03872778
Summary
This early-stage study tested a new two-part radioactive drug for people with advanced solid tumors. First, a scanning agent identified tumors with a specific marker. Then, a therapeutic radioactive version was given to try to treat those tumors. The main goals were to check safety, find the right dose, and see if the treatment showed any signs of fighting the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Addenbroke's hospital
Cambridge, United Kingdom
-
CHU de Grenoble
La Tronche, France
-
City of Hope
Duarte, California, 91010, United States
-
Erasmus MC
Rotterdam, Netherlands
-
John Hopkins University
Baltimore, Maryland, 21287, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Medical University of Innsbruck
Innsbruck, Austria
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Pittsburgh University
Pittsburgh, Pennsylvania, 15213, United States
-
Stanford University
Stanford, California, 94305, United States
-
Vall d'Hebron Institute of Oncology
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.